Imagine trying to solve a puzzle, but every person has only one piece and they aren't allowed to give their piece away. This project creates a secure digital system where researchers can ask questions and get answers from all those pieces without the data ever leaving its original home. It's like a secure library where you can read the books, but you can't take them out of the building.
Rare cancer research is stalled because data is scattered across small sample sizes in different countries. Current privacy laws make it difficult to pool this data into one place for analysis.
A federated data ecosystem consisting of local 'capsules' for secure data processing, AI tools for multi-language analysis, and a data navigator for researchers.
If you are a drug developer dealing with data paucity for rare diseases — this project developed a federated data ecosystem that allows access to aggregated data from 11 centers. This helps identify patient cohorts for clinical trials without moving sensitive data.
If you are a software provider dealing with strict data privacy laws — this project developed 'IDEA4RC capsules' that process data locally. This ensures data never leaves the center while still allowing multi-language analysis via AI tools.
If you are a clinic dealing with rare tumors that affect fewer than 1 in 200,000 people — this project developed a data navigator to find high-quality data. This improves the quality of care and diagnosis for patients across 26 EU Member States.
Based on available project data, no specific pricing or cost model for end-users is mentioned; the project was funded by an EU contribution of EUR 8,190,468.
Yes, the project identifies dissemination towards other European Reference Networks (ERNs) on rare diseases as a pathway to scale.
The project mentions the possible commercial exploitation of developed software technologies, but specific licensing terms are not provided in the report.
It uses a federated approach where data never leaves the local center; only aggregated results are shared, governed by specific data access permits.
The project period runs from 2022-09-01 to 2026-08-31, suggesting full availability after this window.
The consortium is highly diversified with 28 partners across 12 countries. It shows a strong lean toward research and academic institutions (19 total), but maintains a significant industrial presence with 6 companies (21% industry ratio), including 3 SMEs. This balance suggests the project is grounded in deep clinical research while having the necessary commercial perspective for software exploitation.
Contact Fondazione IRCCS Istituto Nazionale dei Tumori in Italy
Contact us to explore licensing opportunities for the IDEA4RC capsules.
